Contents
On this page
- Two meanings of the term and the consequences of ambiguity
- A working taxonomy and the outcomes measured by each type
- Deprescribing as the most extensively evidenced example
- Distinguishing process outcomes from patient outcomes
- Limitations of adherence interventions
- Absence of a suitable licensed product
- Describing the intervention to permit replication
- Applicable reporting checklists
- Limits of the current evidence
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · pharmaceutical interventions
Pharmaceutical Interventions: Definition, Classification and Reporting
The term “pharmaceutical intervention” denotes two unrelated concepts: the administration of a drug as treatment, and action on how drugs are prescribed, supplied or taken. Almost all trial evidence described as pharmaceutical intervention research concerns the second. In that literature, the outcome most reliably achieved is a process outcome, such as fewer medicines or fewer doses, which is distinct from clinical improvement in the patient; this distinction is frequently lost in abstracts.
The term “pharmaceutical intervention” is ambiguous. In one usage, the intervention is the drug; in the other, it is a pharmacist-delivered action on the medication process, such as a medication review, a deprescribing consultation, a compliance aid or a counselling session. Most trials concern the second usage, and their findings are informative in a specific and limited way: of 14 randomised controlled trials of deprescribing in older adults with polypharmacy, 13 (92.9%) found that the intervention reduced the number of drugs or doses taken. This indicates that such interventions reliably achieve their immediate process objective; whether patients benefited is a separate question with less extensive evidence. This article examines the definition, classification and reporting of pharmaceutical interventions.
Learning objectives
- The two concepts denoted by the term, and how to distinguish between them in a title and abstract
- A working taxonomy of pharmacist-delivered interventions, with the outcome each one usually measures
- What the trial evidence on deprescribing establishes, and the limits of that evidence
- Why a reduction in the number of medicines is a process outcome, and how to report it accurately
- The adherence problem that compliance aids do not resolve in isolation
- How to describe an intervention in sufficient detail to permit replication
Common misconceptions
- “Pharmaceutical intervention means giving a drug.” The term is used in this way, but almost all of the randomised evidence published under it concerns pharmacist-delivered actions on prescribing, supply and adherence. Where the drug is meant, the terms “drug treatment” or the name of the agent should be used.
- “Deprescribing trials show that deprescribing improves outcomes.” They show that it reduces drug burden: 13 of 14 randomised controlled trials, or 92.9%, reduced the number of drugs and/or doses taken. Drug count is a process measure. Reporting it as a benefit without stating the effect on the patient is the most common overstatement in this literature.
- “A compliance aid resolves non-adherence.” A compliance aid is insufficient in isolation. Among 61 compliance-aid users, 12 (20%) did not know why the aid had been provided. A patient who cannot explain an intervention cannot be regarded as actively participating in it.
- “Polypharmacy is the problem, so fewer drugs is the objective.” The objective is appropriate prescribing, which may require adding a medicine as readily as discontinuing one. A trial that counts only reductions cannot detect cases in which initiating a medicine was the appropriate decision.
- “The intervention description can be brief because pharmacist review is a familiar activity.” The statement “A pharmacist-led medication review was conducted” names an activity, not an intervention. Without information on who delivered it, with what training, using what criteria, with what authority to change a prescription and over how many contacts, the study cannot be replicated or pooled.
Two meanings of the term and the consequences of ambiguity
“Pharmaceutical intervention” is used for two different categories of thing, and the literature does not consistently mark which is meant.
The drug as the intervention. In this usage the pharmaceutical intervention is the medicine administered — the agent tested against placebo or an active comparator. Here the term is a synonym for drug treatment, and the reporting standards are those of any trial of a therapeutic agent.
The medication process as the intervention. Here the intervention is something done to how medicines are prescribed, dispensed, explained or taken: a structured medication review, a deprescribing consultation, pharmacist-led counselling, a compliance aid, a reconciliation process at discharge, a prescriber feedback loop 4,7. The drug is the context; the intervention is the action on the system around it.
The second usage is where the trial evidence published under this term predominantly sits, and it is also the usage that creates reporting problems, because the intervention is complex, delivered by people, and variable between sites in ways that a drug is not. The ambiguity therefore has two consequences. A reader who assumes the first meaning will misread the abstract, and a reader who assumes the second will look for intervention-description detail that the authors may not have provided.
The remedy requires one word in the title and one sentence in the abstract. Authors should name the agent if the drug is the intervention, and the deliverer and the action if the process is the intervention — “pharmacist-led medication review” rather than “pharmaceutical intervention”. This minor revision prevents an entire category of misreading.
A working taxonomy and the outcomes measured by each type
Pharmacist-delivered interventions are heterogeneous, and the differences matter because each type has a characteristic outcome measure, a characteristic way of succeeding, and a characteristic way of being overstated.
The table sets out the main types. The outcome column shows a dominant pattern: most of these interventions are measured on process outcomes 7,10. These include the number of medicines, the number of potentially inappropriate prescriptions, adherence as measured by pill counts or refill records, and the proportion of discrepancies resolved at discharge. These are legitimate measures of whether the intervention achieved its stated aim; they are not measures of whether the patient benefited.
This is not a criticism of the studies. Process outcomes are the appropriate primary endpoint for an intervention whose mechanism is a change in process, and requiring mortality as an endpoint in a medication-review trial would be unreasonable and usually unachievable at feasible sample sizes. The criticism applies to how the results are reported — specifically, to abstract conclusions that move from a process result to a patient-benefit claim in a single sentence.
A further consideration concerns classification. Where an intervention combines two or three of these types, authors should state this and describe each component, because a successful combined intervention does not indicate which component was responsible for the effect. Complex-intervention reporting guidance exists to address this problem, and it should be consulted at the design stage rather than after the study.
Types of pharmacist-delivered pharmaceutical intervention, and what each one usually measures
| Type | What it acts on | Outcome usually measured | How it is usually overstated |
|---|---|---|---|
| Structured medication review | The current regimen, assessed against explicit criteria | Number of potentially inappropriate prescriptions; recommendations made and implemented | Recommendations made are reported as changes achieved |
| Deprescribing consultation | Stopping or reducing medicines judged no longer appropriate | Number of drugs and/or doses taken | A drug-count reduction is presented as a patient benefit |
| Medicines reconciliation at admission or discharge | Discrepancies between what is prescribed and what the patient takes | Discrepancies identified and resolved | Discrepancy resolution is read as harm prevented |
| Adherence counselling | The patient’s understanding of and intention to take the regimen | Adherence by self-report, pill count or refill records | A refill improvement is read as the patient taking the medicine |
| Compliance aid supply | The mechanics of executing the regimen | Adherence measures; sometimes errors in administration | Non-adherence is assumed to be mechanical when it may be a decision |
| Prescriber feedback or education | The prescriber’s behaviour rather than the patient’s | Prescribing rates for target medicines | A prescribing shift is reported without any patient-level outcome |
| Formulation or licensing work | The absence of a suitable licensed product | Availability of an age- or route-appropriate product | Off-label use is framed as a prescribing error rather than a supply gap |
A working taxonomy for authors, compiled from the intervention types described in the pharmaceutical intervention literature cited for this article. It is not a published classification, and the categories are not mutually exclusive — most interventions in practice combine two or more, which itself presents a reporting problem.
Deprescribing as the most extensively evidenced example
Deprescribing is the clearest illustrative case, because it has the most randomised evidence and the most clearly defined process outcome.
Of 14 randomised controlled trials of deprescribing in older adults with polypharmacy, 13 — 92.9% — found the intervention reduced the number of drugs and/or doses taken 7. A later systematic review and meta-analysis of deprescribing interventions for older patients pooled 32 randomised controlled trials enrolling 18,670 patients aged at least 60 10.
The consistency of this finding is notable. That thirteen of fourteen trials reached the same directional result is a strong signal, and the 32-trial pooled analysis with 18,670 patients is a substantial evidence base by the standards of health services research. Randomised designs have repeatedly shown that a structured deprescribing intervention can reduce the number of medicines an older patient takes.
The nature of the question, however, requires attention. “Reduced the number of drugs and/or doses taken” is a count. It provides no information on falls, hospital admissions, cognition, quality of life, mortality or symptom burden, and it does not distinguish a trial in which the appropriate medicines were stopped from one in which medicines were simply stopped 7,10. The 92.9% figure therefore reflects consistency with the intervention’s own logic.
This matters because the field’s rationale is a patient-outcome rationale: polypharmacy is targeted because it is associated with harm 7. Demonstrating that an intervention reduces drug count is a necessary step towards demonstrating that it reduces that harm, but it is not the same step. In reporting a deprescribing study, authors should present the count result as a count result and report separately, with whatever precision the study actually affords, what happened to the patients.
The deprescribing evidence base. All four figures describe drug-burden outcomes — the number of medicines or doses taken — and not patient outcomes such as admissions, falls or survival. From the randomised trial review and the subsequent systematic review and meta-analysis cited for this article.
Distinguishing process outcomes from patient outcomes
The distinction is standard in health services research, but it warrants explicit statement, because it marks the point at which accurate reporting of this literature diverges from promotional reporting.
A process outcome measures whether the intended change in care occurred: medicines stopped, reviews completed, discrepancies resolved, adherence improved on a refill measure. A patient outcome measures what happened to the person: symptoms, function, admissions, survival, experience.
Process outcomes predominate in this field for three reasons. They are proximal to the intervention, so they respond at feasible sample sizes; they are inexpensive and reliably measurable from records; and they are what the intervention directly acts upon, which makes them the appropriate test of mechanism. All three reasons are sound; the difficulty arises only in the interpretation of the findings.
Two principles make the report accurate without weakening it. First, the process claim and the patient claim should be stated in separate sentences, each accompanied by the evidence that supports it. Second, if the study did not measure patient outcomes, this should be stated as a limitation rather than left to be inferred, and authors should avoid formulations that treat the process result as a proxy. “Reducing inappropriate prescribing is expected to reduce adverse drug events” is a hypothesis; written in a conclusion without that framing, it reads as a result.
There is also an implication for design. If patient outcomes are the objective, they must be specified in the protocol with a realistic sample size; otherwise, the study should be explicitly framed as a mechanism study. Pubrica’s biostatistics support and statistical analysis plan work cover that decision, and epidemiological designs for clinical trials covers what each design can detect.
Limitations of adherence interventions
Adherence interventions have a characteristic failure that warrants attention because it is not detected by the usual outcome measures.
Among 61 compliance-aid users, 12 — 20% — did not know why the aid had been provided 25. One in five people using a device intended to help them take medicines correctly could not state what problem it was intended to address 25.
This finding has implications for the logic of the intervention itself. A compliance aid works by making the regimen easier to execute, which assumes that the patient is attempting to execute it and failing on the mechanics. If the patient does not know why the aid has been provided, two explanations are plausible: the patient was not consulted about what was difficult, or the difficulty was never mechanical 20,25. Non-adherence driven by beliefs about the medicine, by side effects, or by a decision not to take it is not addressed by an improved dispensing device, and an aid supplied without that conversation can improve the record while the patient’s situation remains unchanged.
These findings have two implications for the design and reporting of such studies. The intervention description should include what was explained to the patient and how understanding was checked, because this is a component of the intervention rather than a courtesy. In addition, the outcome measure should capture patient understanding alongside the behavioural measure, because a refill-based adherence improvement in a population of whom one fifth do not know why they have the device should be reported with that context. Pubrica’s patient education content work and plain language summaries cover the comprehension side.
Absence of a suitable licensed product
One category of pharmaceutical intervention responds not to prescribing behaviour but to a gap in available products. About 60% of paediatric formulations are prescribed off-label, which is a persistent target for intervention and a different kind of problem from those described above 10,18.
Off-label prescribing at that scale is not primarily a clinician error to be corrected. It reflects the absence of licensed, age-appropriate formulations for conditions children have, which means the intervention required is formulation development, dosing research and licensing work rather than a medication review 16,18. Our pages on selecting materials for drug development, excipients and paediatric therapeutic work cover that side.
For authors, the relevant point again concerns terminological precision. A study of pharmacist-led interventions to reduce off-label paediatric prescribing is a plausible and useful study. A study arguing that off-label prescribing should be reduced, in a context where no licensed alternative exists, is arguing for the drug not to be given — which may be the wrong recommendation and is certainly a different one. Authors should state explicitly which of these they are undertaking, and whether a licensed alternative was available in the study setting, because the 60% figure describes a supply problem as much as a prescribing one 18.
Describing the intervention to permit replication
Pharmaceutical intervention papers most often fail peer review on methodological grounds at this point, and the deficiency is readily corrected because the required content is specified.
A complete description answers, at minimum: who delivered it and with what training and qualification; exactly what they did, in enough detail to repeat; what materials or tools were used, including any explicit criteria or screening instrument applied; where it happened and in what care setting; how often and over how long; whether it was tailored to the individual patient and on what basis; what authority the deliverer had to change a prescription, which is decisive in pharmacist-led work and almost always omitted; and whether fidelity to the intended intervention was assessed, and what was found.
The authority item deserves emphasis. A pharmacist who can independently alter a prescription is delivering a materially different intervention from one who can only recommend a change to a prescriber who may decline. Trials of both are published as “pharmacist-led medication review”, and a reader cannot tell them apart, nor can a meta-analyst pool them sensibly. Reporting the authority and the uptake rate — what proportion of recommendations were implemented — converts an uninterpretable intervention label into a described one.
The TIDieR checklist specifies this item set for intervention descriptions, and CONSORT covers the surrounding trial report. The comparison below presents the one-sentence version and its corrected form.
The intervention description in a pharmacist-led trial
Names an activity, not an intervention
A pharmacist-led medication review was conducted for all participants in the intervention arm. Recommendations were communicated to the treating physician. The primary outcome was the number of regular medicines at follow-up.
“A medication review was conducted” is an activity label. Duration, number of contacts, setting, and the content of the assessment are all absent, so the study cannot be replicated or pooled with a comparable one.
No deliverer detail. Whether one pharmacist or ten delivered the review, and with what qualification and study-specific training, is unreported, although this is the largest single source of between-study variation in this field.
Prescribing authority unstated. A pharmacist who can change a prescription and one who can only recommend are delivering different interventions; both are published under this label and a reader cannot tell which this is.
“Recommendations were communicated” with no uptake rate. If most recommendations were declined, the intervention that reached the patient is not the intervention described.
No explicit criteria and no fidelity assessment. Without a named screening instrument, the content of the review depends on each pharmacist’s judgement, and nothing establishes that the intended intervention was delivered.
Process outcome as the only outcome, unmarked. Medicine count is the primary endpoint and nothing signals that this is a process measure rather than a patient one.
Replicable, and poolable with comparable studies
Participants in the intervention arm received a single face-to-face medication review of 45 to 60 minutes, delivered in the outpatient clinic by one of three clinical pharmacists, each with postgraduate clinical pharmacy qualification and at least three years of experience in older people’s medicine, who received eight hours of protocol-specific training before the study opened. Each review assessed the full regimen against an explicit screening instrument for potentially inappropriate prescribing, supplemented by a structured discussion of what the patient found difficult about taking their medicines and what they believed each medicine was for. Pharmacists had no independent authority to alter prescriptions; recommendations were sent to the treating physician as a written structured note within two working days, and the physician recorded acceptance or rejection with a reason. Of 412 recommendations made, 263 (63.8%) were implemented within 12 weeks. Review content was tailored to the individual regimen and no component was protocol-mandated beyond the screening instrument. Fidelity was assessed by independent review of a random 10% of consultation records against a four-item delivery checklist, with full delivery recorded in 38 of 41 reviews. The primary outcome was the number of regular medicines at 12 weeks; patient-reported outcomes and hospital admissions were collected as secondary outcomes and are reported separately.
Dose, duration, setting and number of contacts are specified, so the intervention can be replicated and compared with others of the same type.
Deliverer qualification and protocol-specific training are given, which is what makes between-study differences interpretable rather than invisible.
Prescribing authority is stated and the implementation rate is reported, so the reader knows what proportion of the intended intervention actually reached patients.
An explicit screening instrument anchors the review content, and tailoring is described as tailoring rather than left as unexplained variation.
Fidelity is assessed against a stated checklist on a random sample, with the result reported — which converts “the intervention was delivered” from an assumption into a finding.
The primary outcome is identified as a count of medicines and the patient-level outcomes are flagged as separate, which prevents the conclusion from sliding between the two.
A meta-analyst who cannot determine whether the pharmacists could change prescriptions, or how many recommendations were accepted, cannot pool the trial with any other; the second version therefore determines whether the study contributes to the evidence base or remains outside it.
Applicable reporting checklists
The reporting guideline should be matched to the design, and the intervention-description guideline should be applied in addition in every case.
A randomised trial of a pharmaceutical intervention is reported against CONSORT, with the intervention described to TIDieR rather than in the single sentence CONSORT’s intervention item can be satisfied with in a drug trial. An observational study of prescribing or adherence is reported against STROBE, in the cohort or cross-sectional variant as applicable. A quality improvement project — as many of these interventions in fact are — should be reported against SQUIRE, and mislabelling a quality improvement project as a trial is a common and avoidable rejection reason. A systematic review of such interventions sits on PRISMA 2020 — see our page on what PRISMA is and is not.
Two additional considerations are specific to this field. Where the intervention has several components, the complex-intervention reporting considerations apply, and the components must be separable in the description even if they were not separable in delivery. Where an economic argument is made, as is usual with deprescribing, the cost data require their own reporting treatment; Pubrica’s CHEERS guidance and health economics support cover that 14,15.
Limits of the current evidence
Four limits, stated plainly.
It does not establish that deprescribing improves patient outcomes. What 13 of 14 randomised trials establish is a reduction in the number of drugs and/or doses taken, and the 32-trial pooled analysis of 18,670 patients aged at least 60 is an analysis of deprescribing interventions rather than a demonstration of patient benefit 7,10,18. A patient-benefit claim based on this literature requires citation of the specific trials and outcomes that support it, which form a narrower set.
It does not indicate which component of a complex intervention was effective. Most of these interventions combine review, counselling, prescriber communication and sometimes a supply change, and the trial designs cannot separate them 7,10.
It does not establish that reducing medicine counts is the correct objective. Appropriate prescribing can require starting a medicine, and a trial that counts only reductions cannot detect that case 4. The 92.9% figure should not be read as 92.9% of interventions getting prescribing right.
Similarly, the finding that 20% of compliance-aid users did not know why the aid was provided derives from 61 users in one setting 25. The finding is specific and useful as a warning about intervention delivery; it is not a prevalence estimate for aid users generally, and this page does not treat it as one.
Key points
Key points
The term “pharmaceutical intervention” covers both the administration of a drug and action on the medication process, and almost all the randomised evidence under the term concerns the second; authors should therefore name the deliverer and the action rather than using the phrase. In that literature, the consistent finding is a process finding: 13 of 14 randomised controlled trials of deprescribing in older adults with polypharmacy, or 92.9%, reduced the number of drugs and/or doses taken, and a later systematic review and meta-analysis pooled 32 randomised trials enrolling 18,670 patients aged at least 60. Drug count is a process outcome, and reporting it separately from any claim of patient benefit is the most important principle of accurate reporting in this field. Two further cautions apply: appropriate prescribing may involve initiating a medicine, so a reduction is not necessarily a success; and a patient who cannot explain an intervention cannot be regarded as participating in it, as illustrated by the finding that 12 of 61 compliance-aid users did not know why the aid was provided. The intervention should then be described according to TIDieR, including the item most frequently omitted: whether the pharmacist could change a prescription, and how many recommendations were implemented.
Application to your study
Application to your study
- The intervention should be named precisely in the title. Terms such as “pharmacist-led medication review” or the name of the drug should be used in preference to “pharmaceutical intervention”, which a substantial proportion of readers will interpret incorrectly.
- The primary outcome should be classified as a process or patient outcome in the protocol. If it is a count of medicines, prescriptions or discrepancies, it is a process outcome, and the report should state this.
- Process claims and patient claims should be stated in separate sentences. Each claim should be accompanied by its supporting evidence, with the limitation stated where patient outcomes were not measured.
- The prescribing authority and the implementation rate should be reported. Authors should state whether the deliverer could change a prescription independently and what proportion of recommendations were implemented.
- The intervention should be described according to TIDieR before submission. The description should specify who delivered it, what was delivered, with what materials and criteria, where, how often, for how long, how it was tailored, and how fidelity was assessed, with the result.
- The components of a bundled intervention should be described separately. This applies even where components were delivered together, so that a subsequent review can identify the content of each version.
- Patient understanding should be measured alongside behaviour in adherence studies. An improvement in refill rates in a population of whom one fifth cannot explain the intervention should be reported with that context.
- The availability of a licensed alternative should be established before off-label use is characterised as an error. With approximately 60% of paediatric formulations prescribed off-label, the problem frequently concerns supply rather than prescribing.
Frequently asked questions
The term is used for two different things. In the first sense the intervention is the drug itself — the medicine administered and tested against a comparator. In the second, which accounts for most of the randomised evidence published under the term, the intervention is an action on the medication process: a structured medication review, a deprescribing consultation, medicines reconciliation at admission or discharge, adherence counselling, a compliance aid, or prescriber feedback. The drug is the context and the intervention is the action on the system around it. Because the two meanings carry different reporting requirements and different reader expectations, authors are advised to avoid the phrase and to name the intended referent: the agent, or the deliverer and the action.
It reliably achieves its intended process objective. Of 14 randomised controlled trials of deprescribing in older adults with polypharmacy, 13 — 92.9% — found the intervention reduced the number of drugs and/or doses taken, and a later systematic review and meta-analysis pooled 32 randomised controlled trials enrolling 18,670 patients aged at least 60. This is a substantial and consistent evidence base for the proposition that a structured deprescribing intervention reduces drug burden. It is not evidence that patients benefit, because drug count is a process measure: it provides no information on falls, admissions, cognition, quality of life or survival, and it does not distinguish stopping the appropriate medicines from simply stopping medicines. A patient-benefit claim requires citation of the narrower set of trials that measured patient outcomes.
A process outcome measures whether the intended change in care occurred: medicines stopped, reviews completed, discrepancies resolved, refill-based adherence improved. A patient outcome measures what happened to the person: symptoms, function, admissions, survival, experience. Process outcomes dominate this field for three sound reasons — they are proximal to the intervention and so respond at feasible sample sizes, they are inexpensive and reliable to measure from records, and they are the appropriate test of the intervention’s mechanism. The difficulty lies only in the reporting, where a conclusion moves from a count to a benefit in one sentence. The two should be stated in separate sentences, each accompanied by its supporting evidence, and the absence of patient outcomes should be stated as a limitation rather than implying a proxy.
Because they address one cause of non-adherence and are often supplied without checking whether that cause applies. Among 61 compliance-aid users, 12 — 20% — did not know why the aid had been provided. A compliance aid works by making a regimen easier to execute, which presupposes a patient who is attempting to adhere and failing on the mechanics. Non-adherence driven by beliefs about the medicine, by side effects, or by a deliberate decision not to take it is not addressed by an improved dispensing device, and an aid supplied without that conversation can improve the record while leaving the patient’s situation unchanged. The implication for design is that what was explained to the patient, and how understanding was checked, are part of the intervention and belong in its description.
As an objective it is a proxy, and sometimes an inappropriate one. The goal of a medication intervention is appropriate prescribing, and appropriateness can require starting a medicine as readily as stopping one — an under-treated condition is as much a prescribing failure as an unnecessary drug. A trial that counts only reductions cannot detect cases in which the correct action was an addition, so 13 of 14 trials reducing drug burden should not be read as 13 of 14 interventions achieving appropriate prescribing. When designing a study, appropriateness should be defined against an explicit instrument and additions recorded alongside discontinuations, so that the result describes the direction of change in appropriateness rather than only its magnitude in one direction.
According to the item set TIDieR specifies, which requires reporting: who delivered it, with what qualification and what protocol-specific training; what was done, in replicable detail; what materials or explicit criteria were used; where, and in what care setting; how often and over what period; whether and how it was tailored; and whether fidelity was assessed and what was found. The one item almost always omitted in this field should be added: what authority the deliverer had to change a prescription, and what proportion of recommendations were implemented. A pharmacist who can alter a prescription independently is delivering a materially different intervention from one who can only recommend, and both are published as “pharmacist-led medication review” — which makes the published literature difficult to pool.
The guideline should be matched to the design, and an intervention-description guideline added in every case. A randomised trial is reported against CONSORT, with the intervention described to TIDieR rather than in the single sentence that suffices for a drug. An observational study of prescribing or adherence is reported against STROBE, in its cohort or cross-sectional variant. A quality improvement project — as many of these interventions are — should be reported against SQUIRE, and labelling one as a trial is a common and avoidable reason for rejection. A systematic review is reported against PRISMA 2020. If the intervention has several components, complex-intervention reporting considerations apply and the components must be separable in the description; if an economic argument is made, the cost data require separate treatment under CHEERS.
It is, although often not in the way commonly assumed. About 60% of paediatric formulations are prescribed off-label, and at that scale the driver is largely the absence of licensed, age-appropriate products rather than clinician error. This changes the intervention required: formulation development, dosing research and licensing work, rather than a medication review aimed at changing prescriber behaviour. A study of pharmacist-led work to reduce off-label paediatric prescribing is reasonable; a study arguing that off-label prescribing should be reduced where no licensed alternative exists is arguing for the medicine not to be given, which is a different and possibly inappropriate recommendation. Authors should state which of these they are undertaking, and whether a licensed alternative was available in the study setting.
References
- U.S. Food and Drug Administration. Container Closure Systems for Human Drugs and Biological Products (draft guidance). U.S. Food and Drug Administration. 2026. read 9 October 2026. packagingdigest.com
- U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Carollo M, Cristini I, Crisafulli S, Fontana A, Forti A, Lanaro A, Maccarrone F, Zerio M, Piccoli L, Poluzzi E, Onder G, Trifiro G. Evaluating the impact of medication review and deprescribing on prescribing appropriateness and clinical outcomes in older people residing in long-term care facilities: a systematic review and meta-analysis. 2026. doi:10.1093/ageing/afag084 read 9 October 2026. doi.org/10.1093/ageing/afag084
- Comoglu T, Ozyilmaz ED. Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives. Pharmaceutical Development and Technology. 2025;30(1):1-9. doi:10.1080/10837450.2024.2441181 read 9 October 2026. doi.org/10.1080/10837450.2024.2441181
- Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721. doi:10.1002/jgm.3721 read 9 October 2026. doi.org/10.1002/jgm.3721
- Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. International Journal of Pharmacy Practice. 2023;31(4):349-368. doi:10.1093/ijpp/riad025 read 9 October 2026. doi.org/10.1093/ijpp/riad025
- Jain S, Kaur S, Rathi R, Nagaich U, Singh I. Application of co-processed excipients for developing fast disintegrating tablets: A review. Polymers in Medicine. 2023;53(1):59-68. doi:10.17219/pim/158009 read 9 October 2026. doi.org/10.17219/pim/158009
- Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
- Deprescribing Interventions for Older Patients: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2023. doi:10.1016/j.jamda.2023.07.016 read 9 October 2026. doi.org/10.1016/j.jamda.2023.07.016
- Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
- Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Therapy. 2023;30(10-11):738-746. doi:10.1038/s41434-023-00390-5 read 9 October 2026. doi.org/10.1038/s41434-023-00390-5
- Kadakia KT, Dhruva SS, Caraballo C, et al. Use of recalled devices in new device authorizations under the US Food and Drug Administration's 510(k) pathway and risk of subsequent recalls. JAMA. 2023;329:136-143. read 9 October 2026. tctmd.com
- Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Explanation and Elaboration: A report of the ISPOR CHEERS II Good Practices Task Force. Value in Health. 2022;25(1):10-31. read 9 October 2026. ispor.org
- Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975. read 9 October 2026. cris.iucc.ac.il
- Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
- Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
- Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
- Carli Lorenzini G, Olsson A. DESIGN TOWARDS BETTER LIFE EXPERIENCE: CLOSING THE GAP BETWEEN PHARMACEUTICAL PACKAGING DESIGN AND ELDERLY PEOPLE. DS 80-9 Proceedings of the 20th International Conference on Engineering Design (ICED 15). 2015;9:065-076. read 9 October 2026. designsociety.org
- Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
- Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. The Lancet Oncology. 2015;16(10). read 9 October 2026. oncology-central.com
- Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
- Mitera G, Swaminath A, Rudoler D, Seereeram C, Giuliani M, Leighl N, Gutierrez E, Dobrow MJ, Coyte PC, Yung T. Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer. JCO Oncology Practice. 2014;10(3):e130-e136. doi:10.1200/jop.2013.001206 read 9 October 2026. doi.org/10.1200/jop.2013.001206
- Chin K, Hegarty A, Thielemans L, Schiff R. Thinking outside the box: exploring user and carer perceptions of pharmacy-filled multi-compartment medication compliance aids. doi:10.83033/54ab2e80-a44b-47ec-9043-4b97ca598aba read 9 October 2026. doi.org/10.83033/54ab2e80-a44b-47ec-9043-4b97ca598aba
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Pharmaceutical Interventions: Definition, Classification and Reporting. Pubrica. https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/
Pubrica Academy. “Pharmaceutical Interventions: Definition, Classification and Reporting.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/.
Pubrica Academy (2026) Pharmaceutical Interventions: Definition, Classification and Reporting. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/ (Accessed: 15 October 2026).
Pubrica Academy. “Pharmaceutical Interventions: Definition, Classification and Reporting.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/
Pubrica Academy, ‘Pharmaceutical Interventions: Definition, Classification and Reporting’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/> accessed 15 October 2026.
Pubrica Academy. Pharmaceutical Interventions: Definition, Classification and Reporting. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/
Pubrica Academy, “Pharmaceutical Interventions: Definition, Classification and Reporting,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/
@misc{use_of_pharmaceutical_interventions_2026,
author = {{Pubrica Academy}},
title = {Pharmaceutical Interventions: Definition, Classification and Reporting},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/use-of-pharmaceutical-interventions/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Intervention description and outcome-labelling worksheet
Part one classifies each outcome before the abstract is written, because the abstract is where process and patient claims are most often conflated. Part two is the TIDieR-aligned description, including the prescribing-authority items that this field routinely omits. The checklist should be completed before submission; an unfilled line is likely to prompt a reviewer query.
PHARMACEUTICAL INTERVENTION: DESCRIPTION AND OUTCOME WORKSHEET
STUDY: ______________________________________________
DESIGN: [ ] RCT [ ] observational [ ] QI project
[ ] systematic review [ ] other: ______________
PART 0 — WHICH KIND OF INTERVENTION IS THIS?
[ ] A drug given as treatment -> name the agent in the title
[ ] An action on the medication process -> name the deliverer
and the action in the title
Title as it currently reads: ________________________________
[ ] The title does NOT use the bare phrase "pharmaceutical
intervention"
PART 1 — OUTCOME LABELLING (do this before the abstract)
PRIMARY OUTCOME: ___________________________________
This is a: [ ] PROCESS outcome (a count of medicines,
prescriptions, discrepancies, reviews, refills)
[ ] PATIENT outcome (symptoms, function,
admissions, survival, experience)
SECONDARY OUTCOMES, each labelled P (process) or Pt (patient):
1. ____________________________ [ ]P [ ]Pt
2. ____________________________ [ ]P [ ]Pt
3. ____________________________ [ ]P [ ]Pt
4. ____________________________ [ ]P [ ]Pt
[ ] If NO patient outcome was measured, this is stated as a
limitation in the discussion, in these words:
"____________________________________________"
[ ] The abstract conclusion makes NO patient-benefit claim that
a process outcome cannot support
[ ] Process claim and patient claim are in SEPARATE sentences
DIRECTION OF CHANGE (deprescribing and review studies):
Medicines stopped: ______ Medicines STARTED: ______
[ ] Additions are recorded and reported, not only reductions
Appropriateness instrument used: ______________________
PART 2 — INTERVENTION DESCRIPTION (TIDieR-aligned)
WHY — rationale / theory for this intervention:
____________________________________________________
WHAT (materials) — tools, forms, screening instrument,
patient-facing materials: __________________________
Explicit criteria or instrument named: ______________
WHAT (procedures) — what was actually done, step by step:
____________________________________________________
____________________________________________________
WHO PROVIDED IT
Number of deliverers: ______
Professional group: ______________________
Qualification: ______________________
Experience required: ______________________
Protocol-specific training given: ______ hours, covering
____________________________________________
HOW — mode of delivery:
[ ] face to face [ ] telephone [ ] video [ ] written
[ ] individual [ ] group
WHERE — setting and care level: ____________________
WHEN AND HOW MUCH
Number of contacts: ______ Duration of each: ______ min
Period over which delivered: ______________
TAILORING
[ ] not tailored [ ] tailored on: ______________________
MODIFICATIONS during the study: ______________________
FIDELITY
Assessed? [ ] no [ ] yes — how: ______________________
Sample assessed: ______ Result: ______________________
PART 3 — THE ITEMS THIS FIELD OMITS (do not skip)
PRESCRIBING AUTHORITY of the deliverer:
[ ] could alter prescriptions independently
[ ] could recommend only; prescriber decided
[ ] other: ______________________
RECOMMENDATION UPTAKE
Recommendations made: ______
Implemented: ______ ( ______% ) within ______ weeks
Reasons recorded for non-implementation? [ ] yes [ ] no
PATIENT UNDERSTANDING (adherence and aid studies)
What was explained to the patient: ______________________
How understanding was checked: __________________________
[ ] Understanding reported as an outcome, not assumed
COMPONENTS, if bundled — list separately:
1. ____________________ 2. ____________________
3. ____________________ 4. ____________________
[ ] Each component is separable in the written description
PART 4 — REPORTING GUIDELINE
[ ] CONSORT (randomised trial) + TIDieR
[ ] STROBE (observational) + TIDieR
[ ] SQUIRE (quality improvement) + TIDieR
[ ] PRISMA 2020 (systematic review)
[ ] CHEERS (economic evaluation alongside)
[ ] Completed checklist attached with section locations Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica provides two specific services for these manuscripts. The team classifies every outcome in the protocol or draft as a process or patient outcome and revises the conclusion of the abstract so that it claims only what the measured outcome supports, which is the most common correction required in this literature. The team also extends the intervention description to the full TIDieR item set, including the detail on prescribing authority and uptake of recommendations that pharmacist-led studies frequently omit and that determines whether a subsequent systematic review can pool the trial.